Targeting microRNAs in cancer: Rationale, strategies and challenges

Nature Reviews Drug Discovery

Volumn 9, Issue 10, 2010, Pages 775-789

  Garzon, Ramiro ^a   Marcucci, Guido ^b   Croce, Carlo M ^b  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; AZACITIDINE; LOCKED NUCLEIC ACID; MICRORNA; MICRORNA 122; MICRORNA 155; MICRORNA 15A; MICRORNA 16 1; MICRORNA 17 92; MICRORNA 21; MICRORNA 26A; MICRORNA 29A; MICRORNA 29B 1; MICRORNA 29B 2; MICRORNA 29C; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 372; MICRORNA 373; PARVOVIRUS VECTOR; PHOSPHOROTHIOIC ACID; RETINOIC ACID; SHORT HAIRPIN RNA; SPC 3649; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER INVASION; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLON CANCER; CYTOKINE RELEASE SYNDROME; DOWN REGULATION; DRUG DOSE COMPARISON; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; HEPATITIS C; HUMAN; LIVER CANCER; LIVER INJURY; LUNG CANCER; MALIGNANT TRANSFORMATION; MANTLE CELL LYMPHOMA; METASTASIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; ONCOGENE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; REVIEW; RHABDOMYOSARCOMA; RNA PROCESSING; STOMACH CANCER; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION PROFILING; GENE TARGETING; GENETICS; METABOLISM; NEOPLASMS; PROCEDURES; TRENDS;

ANIMALS; GENE EXPRESSION PROFILING; GENE TARGETING; HUMANS; MICRORNAS; NEOPLASMS;

EID: 77957361864     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3179     Document Type: Review

References (136)

1. Ambros, V. The functions of animal microRNAs. Nature 431, 350-355 (2004).
2. Rodriguez, A., Griffiths-Jones, S., Ashurst, J. L. & Bradley, A. Identification of mammalian microRNA host genes and transcription units, Genome Res. 14, 1902-1910 (2004).
3. Lee, Y. et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 23, 4051-4060 (2004).
4. Lee, Y., Ahn, C., Han, J., Choi, H. & Kim, J. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419 (2003).
5. Landthaler, M., Yalcin, A. & Tuschl, T. The human DiGeorge syndrome critical region gene 8 and its D. melanogaster homolog are required for miRNA Biogenesis, Curr. Biol. 14, 2162-2167 (2004).
6. Bohnsack, M. T., Czaplinski, K. & Gorlich, D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 10, 185-191 (2004).
7. Hammond, S., Bernstein, E., Beach, D. & Hannon, G. An RNA-directed nuclease mediates posttranscriptional gene silencing in Drosophila cells. Nature 404, 293-1229 (2000).
8. Thimmaiah, P. et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436, 740-744 (2005).
9. Hutvanger, G. & Zamore, P. D. A microRNA in a multiple-turnover RNAi enxyme complex. Science 297, 2056-2060 (2002).
10. Lewis, B., Shih, I., Jones-Rhoades, M., Bartel, D. & Burge, C. Prediction of mammalian microRNA targets. Cell 115, 787-798 (2003).
11. Krek, D. et al. Combinatorial microRNA target predictions. Nature Genet. 37, 495-500 (2005).
12. Betel, D., Wilson, M., Gabow, A., Marks, D. S. & Sander, C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 36, D149-D153 (2008).
13. Friedman, R. C., Farh, K. K., Burge, C. B. & Bartel, D. P. Most mammalian mRNAs are conserved targets of microRNAs, Genome Res. 19, 92-105 (2009).
14. Ivanovska, I. & Cleary, M. A. Combinatorial microRNAs: working together to make a difference. Cell Cycle 20, 3137-3142 (2008).
15. Stark, A. et al. Discovery of functional elements in 12 Drosophila genomes using evolutionary signatures. Nature 450, 219-232 (2007). (Pubitemid 350100553)
16. Ørom, U. A., Nielsen, F. N. & Lund, A. H. MicroRNA-10a binds the 5?UTR of ribosomal protein mRNAs and enhances their translation. Mol. Cell 4, 460-471 (2008).
17. Eiring, A. et al. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140, 652-665 (2010).
18. Beitzinger, M. & Meister, G. MicroRNAs: from decay to decoy. Cell 140, 612-614 (2010).
19. Khraiwesh, B. et al. Transcriptional control of gene expression by microRNAs. Cell 140, 112-122 (2010).
20. Gonzalez, S., Pisano, D. G. & Serrano, M. Mechanistic principles of chromatin remodeling guided by siRNAs and miRNAs. Cell Cycle 7, 2601-2608 (2008).
21. Kim, D. H., Saetrom, P., Snøve, O. Jr & Rossi, J. J. MicroRNA directed transcriptional gene silencing in mammalian cells, Proc. Natl Acad. Sci. USA 105, 16230-16235 (2008).
22. Calin, G. A. et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia, Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002).
23. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
24. Volinia, S. et al. A microRNA expression signature in human solid tumors defines cancer targets, Proc. Natl Acad. Sci. USA 103, 2257-2261 (2005).
25. Ota, A. et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma, Cancer Res. 64, 3087-3095 (2004).
26. Petrocca, F. et al. E2F1-regulated microRNAs impair TGFβ-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13, 272-286 (2008).
27. Yanaihara, N. et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9, 189-198 (2006).
28. Diosdado, B. et al. MiR-17-92 cluster is associated with 13q gain and c-myc expression during colorectal adenoma to adenocarcinoma progression, Br. J. Cancer 101, 707-714 (2009).
29. Calin, G. A. et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia, N. Engl. J. Med. 353, 1793 -1801 (2005).
30. Iorio, M. V. et al. MicroRNA gene expression deregulation in human breast cancer, Cancer Res. 65, 7065-7070 (2005).
31. Garzon, R. et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111, 3183-3189 (2008).
32. Schetter, A. J. et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425-436 (2008).
33. Ciafre, S. A. et al. Extensive modulation of a set of microRNAs in primary glioblastoma, Biochem. Biophys. Res. Commun. 334, 1351-1358 (2005).
34. Bloomston, M. et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297, 1901-1908 (2007).
35. Pichiorri, F. et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis, Proc. Natl Acad. Sci. USA 105, 12885-12890 (2008).
36. Metzler, M. et al. High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 39, 167-169 (2004).
37. Kluiver, J. et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas, J. Pathol. 207, 243-249 (2005).
38. Garzon, R. et al. Distinctive miRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin, Proc. Natl Acad. Sci. USA 105, 3945-3950 (2008).
39. Wang, H. et al. NF-αB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer Cell 14, 369-381 (2008).
40. Mott, J. L., Kobayashi, S., Bronk, S. F. & Gores, G. J. Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26, 6133-6140 (2007).
41. Xiong, Y. et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 51, 836-845(2010).
42. Zhao, J. J. et al. MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 115, 2630-2639 (2010).
43. Bonci, D. et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Med. 14, 1271-1277 (2008).
44. Bottoni, A. et al. MiR-15a and miR-16-1 downregulation in pituitary adenomas, J. Cell Physiol. 204, 280-285 (2005).
45. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005).
46. Takamizawa, J. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival, Cancer Res. 64, 3753-3756 (2004).
47. Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 (2007).
48. Akao, Y., Nakagawa, Y. & Naoe, T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol. Pharm. Bull. 29, 903-906 (2006).
49. Yang, N. et al. MicroRNA microarray identifies let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer, Cancer Res. 68, 10307-10314 (2008).
50. Motoyama, K. et al. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family, Clin. Cancer Res. 14, 2334-2340 (2008).
51. Calin, G. A. et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers, Proc. Natl Acad. Sci. USA 101, 2999-3004 (2004).
52. Saito, Y. et al. Specific activation of microRNAs-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435-443 (2006).
53. Lujambio, A. et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells, Cancer Res. 67, 1424-1429 (2007).
54. Hackanson, B. et al. Epigenetic modification of CCAAT/enhancer binding protein α expression in acute myeloid leukemia, Cancer Res. 68, 3142-3151 (2008).
55. Kumar, M. S. et al. Dicer1 functions as a haploinsufficient tumor suppressor, Genes Dev. 23, 2700-2704 (2009).
56. Merritt, WA. et al. Dicer, drosha, and outcomes in patients with ovarian cancer, N. Engl. J. Med. 359, 2641-2650 (2008).
57. He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134 (2007).
58. Chang, T. C. et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26, 745-752 (2007).
59. Chang, T. S. et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics 40, 43-50 (2007).
60. Cimmino, A. et al. miR-15 and miR-16 induce apoptosis by targeting BCL2, Proc. Natl Acad. Sci. USA 102, 13944-13949 (2006).
61. Klein, U. et al. The DLEU2/miR-15a/16-11 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 17, 28-40 (2010).
62. Garzon, R. et al. MicroRNA-29 functions in AML. Blood 114, 5331-5341(2009).
63. Sampson, V. B. et al. MicroRNA let-7a downregulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells, Cancer Res. 67, 9762-9770 (2007).
64. Lujambio, A. et al. A microRNA DNA methylation signature for human cancer metastasis, Proc. Natl Acad. Sci. USA 105, 13556-13561 (2008).
65. Chan, J. A., Krichevsky, A. M. & Kosik, K. S. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells, Cancer Res. 65, 6029-6033 (2005).
66. Meng. F. et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658 (2007).
67. Frankel, LB. et al. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 283, 1026-1033 (2008).
68. He, L. et al. A microRNA polycistron as a potential human oncogene. Nature 435, 828-833 (2005).
69. Xiao, C. et al. Lymphoproliferative disease and autoimmunity in mice with elevated miR-17-92 expression in lymphocytes. Nature Immunol. 9, 405-414 (2008).
70. Ventura, A. et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875-886 (2008).
71. Mu, P. et al. Genetic dissection of the miR-17-92 cluster of microRNAs in Myc-induced B-cell lymphomas, Genes Dev. 23, 2806-2811 (2009).
72. Olive, V. et al. miR-19 is a key oncogenic component of miR-17-92, Genes Dev. 23, 2839-2849 (2009).
73. Costinean, S. et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eα-miR155 transgenic mice, Proc. Natl Acad. Sci. USA 103, 7024-7029 (2006).
74. O?Connell, R. M. et al. Sustained expression of micro-RNA-155 in hematopoietic stem cells causes a myeloproliferative disorder, J. Exp. Med. 205, 585-594 (2008).
75. O?Connell, R. M., Chaudhuri, A, A., Rao, D. S. & Baltimore, D. Inositol phosphatase SHIP1 is a primary target of miR-155, Proc. Natl Acad. Sci. USA 106, 7113-7118 (2009).
76. Costinean, S. et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein β are targeted by miR-155 in B cells of Eα-MiR-155 transgenic mice. Blood 114, 1374-1382 (2009).
77. Liu, Q. et al. The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling, J. Exp. Med. 188, 1333-1342 (1998).
78. Ma, L, Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682-688 (2007).
79. Ma, L. et al. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nature Biotechnol. 28, 341-347 (2010).
80. Tavazoie, S. F. et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451, 147-152 (2008).
81. Linsley, P. S. et al. Transcripts targeted by the microRNA-16 family cooperatively regulates cell cycle progression. Mol. Cell Biol. 27, 2240-2252 (2007).
82. Calin, G. A. et al. MiR-15a and miR-16-1 cluster functions in human leukemia, Proc. Natl Acad. Sci. USA 105, 5166-5171 (2008).
83. Li, Q. J. et al. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129, 147-161 (2007).
84. Croce, C. M. Oncogenes and cancer, N. Engl. J. Med. 358, 502-511(2008).
85. Boutla, A., Delidakis, C. & Tabler, M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative targets. Nucleic Acids Res. 31, 4973-4980 (2003).
86. Hutzvanger, G., Simard, M. J., Mello, C. C. & Zamore, P. D. Sequence specific inhibition of small RNA function, PLoS Biol. 2, E98 (2004).
87. Weiler, J., Hunziker, J. & Hall, J. Anti-miRNA oligonucleotides (AMOs); amunition to target miRNAs implicated in human disease? Gene Therapy 13, 496-502 (2006).
88. Krutzfeldt, J. et al. Silencing of microRNAs in vivo with ?antagomirs?. Nature 438, 685-689 (2005).
89. Vester, B. & Wengel, J. LNA (locked nucleic acid): high affinity targeting of complementary RNA and DNA. Biochemistry 43, 13233-13241 (2004).
90. Elmén, J. et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36, 1153-1162 (2008).
91. Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M. & Sarnow, P. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309, 1577-1581 (2005).
92. Elmén, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008).
93. Lanford, R. E. et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis c virus infection. Science 327, 198-201 (2010).
94. Ebert, M. S., Neilson, J. R. & Sharp, P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nature Methods 4, 721-726 (2007).
95. Xiao, J. et al. Novel approaches for gene-specific interference via manipulating actions of micro-RNAs: examination on the pacemaker channel genes HCN2 and HCN4, J. Cell Physiol. 212, 285-292 (2007).
96. Loya, C. M., Lu, C. S., Van Vactor, D. & Fulga, T. A. Transgenic microRNA inhibition with spatiotemporal specificity in intact organisms. Nature Methods 6, 897-903 (2009).
97. Choi, W. Y., Giraldez, A. J. & Schier, A. F. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 318, 271-274 (2007).
98. Gumireddy, K. et al. Small-molecule inhibitors of microrna miR-21 function. Angew. Chem. Int. Ed. Engl. 47, 7482-7484 (2008).
99. Michelfelder, S. & Trepel, M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv. Genet. 67, 29-60 (2009).
100. Aagaard, L. & Rossi, J. J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 59, 75-86 (2007).
101. Kota, J. et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009).
102. Garzon, R. et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26, 4148-4157 (2007).
103. Roccaro, A. et al. MicroRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood 113, 4391-4402 (2009).
104. Galm, O., Herman, J. G. & Baylin, S. B. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev. 20, 1-13 (2006).
105. Lamb, J. et al. The connectivity map: using geneexpression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
106. Zhao, X. et al. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Exp. Opin. Drug Deliv. 6, 673-686 (2009).
107. Dias, N. & Stein, C. A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1, 347-355 (2002).
108. Malik, R. & Roy, L. Design and development of antisense drugs. Exp. Opin. Drug Discov. 3, 1189-1207 (2008).
109. Chiarantini, L. et al. Comparison of a novel delivery systems for antisense peptide nucleic acids. J. Control. Release 109, 24-36 (2005).
110. Zuhorn, I. S., Engberts, J. B. & Hoeckstra, D. Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur. Biophys. J. 36; 349-362 (2007).
111. Chirila, T. V. et al. The use of synthethic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 23, 321-342 (2002).
112. Rosi, N. L. et al. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312, 1027-1030 (2006).
113. Li, Z. et al. Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. J. Biol. Chem. 284, 15676-15684 (2009).
114. Xu, H., Cheung, I. Y., Guo, H. F. & Cheung, N. K. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors, Cancer Res. 69, 6275-6281 (2009).
115. Hornung, V. et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263-270 (2005).
116. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
117. Garzon, R. et al. MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113, 6411-6418 (2009).
118. Fabbri, M. et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B, Proc. Natl Acad. Sci. USA 104, 15805-15810 (2007).
119. Thai, T. H. et al. Regulation of the germinal center response by microRNA-155. Science 316, 604-608 (2007).
120. Rodriguez, A. et al. Requirement of bic/microRNA-155 for normal immune function. Science 316, 608-611 (2007).
121. Kotani, Ai. et al. miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 114, 4169-4178 (2009).
122. Pekarsky, Y. et al. Tcl1 expression in CLL is regulated by miR-29 and miR-181, Cancer Res. 66, 1590-11593 (2006).
123. Trang, P. et al. Regression of murine lung tumors by the let-7 microRNA. Oncogene 29, 1580-1587 (2010).
124. Lee, Y. S. & Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene, Genes Dev. 21, 1025-1030 (2007).
125. Lodygin, D. et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7, 2591-2600 (2008).
126. Toyota, M. et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer, Cancer Res. 68, 4123-4132 (2008).
127. Sun, F. et al. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 582, 1564-1568 (2008).
128. Yamakuchi, M., Ferlito, M. & Lowenstein, C. J. miR-34a repression of SIRT1 regulates apoptosis, Proc. Natl Acad. Sci. USA 105, 13421-13426 (2008).
129. Pigazzi, M., Manara, E., Baron, E. & Basso, G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia, Cancer Res. 69, 2471-2478 (2009).
130. Cole, K. A. et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol, Cancer Res. 6, 735-742 (2008).
131. Li, Z. et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations, Proc. Natl Acad. Sci. USA 105, 15535-15540 (2008).
132. O?Donnell, K. A. et al. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435, 839-843 (2005).
133. Velu, C. S., Baktula, A. M. & Grimes, H. L. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood 113, 4720-4728 (2009).
134. Löffler, D. et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110, 1330-1333 (2007).
135. Zhu, S., Si., M-L, Wu, H. & Mo, Y. Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 282, 14328-14336 (2007).
136. Voorhoeve, P. M. et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124, 1169-1181 (2007).